Highlights and Quick Summary
- Common Equity (Total) for the quarter ending June 30, 2023 was $297 Million (a -5.12% decrease compared to previous quarter)
- Year-over-year quarterly Common Equity (Total) decreased by -12.95%
- Annual Common Equity (Total) for 2022 was $327 Million (a -14.35% decrease from previous year)
- Annual Common Equity (Total) for 2021 was $382 Million (a -3477.2% decrease from previous year)
- Annual Common Equity (Total) for 2020 was $-11.3 Million (a 210.68% increase from previous year)
Visit stockrow.com/DSGN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Common Equity (Total) of Design Therapeutics, Inc.
Most recent Common Equity (Total)of DSGN including historical data for past 10 years.Interactive Chart of Common Equity (Total) of Design Therapeutics, Inc.
Design Therapeutics, Inc. Common Equity (Total) for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $296.8 | $312.82 | – | – | – |
| 2022 | $327.31 | $340.94 | $357.16 | $370.31 | $327.31 |
| 2021 | $382.13 | $391.56 | $401.6 | $408.01 | $382.13 |
| 2020 | – | – | – | $-11.32 | $-11.32 |
| 2019 | – | – | – | – | $-3.64 |
Business Profile of Design Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology